Original language | English |
---|---|
Pages (from-to) | 1509-1510 |
Number of pages | 2 |
Journal | Neurology |
Volume | 73 |
Issue number | 18 |
DOIs | |
State | Published - Nov 2009 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Neurology, Vol. 73, No. 18, 11.2009, p. 1509-1510.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - MGMT methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma
AU - Gerstner, Elizabeth R.
AU - Yip, S.
AU - Wang, D. L.
AU - Louis, D. N.
AU - Iafrate, A. J.
AU - Batchelor, T. T.
N1 - Funding Information: Disclosure: Dr. Gerstner is funded by a K12 training grant (awarded to Dr. Batchelor). Dr. Yip is funded by a Royal College of Physicians and Surgeons of Canada Clinical Investigator Fellowship. D.L. Wang reports no disclosures. Dr. Louis served on scientific advisory boards for the Brain Tumor Society and the Henry Ford Hermlin Brain Tumor Center; has received honoraria from Alnylam Pharmaceuticals and Biogen Idec; his department performs clinical testing for MGMT status and bills for the testing; receives royalties from publishing Greenfield's Neuropathology (Arnold Publishing, 2008–2009) and UpToDate (UpToDate Publishing, 2006–2009); receives research support from the NIH [RO1CA57683 (PI)] and the Simches Endowed Fund for Brain Tumor Research; and has served as an expert witness in brain tumor–related cases. Dr. Iafrate receives research support from AstraZeneca, Fidelity Foundation, and Aid for Cancer Research Foundation; and serves as a consultant for Pfizer, Inc. Dr. Batchelor is on the speakers' bureaus of Schering-Plough Corp. and Enzon Pharmaceuticals, Inc.; serves as consultant/on scientific advisory boards for Acceleron Pharma, AstraZeneca, EMD-Serono, Exelixis Inc., ImClone Systems, Genentech, Inc., Millennium Pharmaceuticals, Inc., and Vertex Pharmaceuticals; serves on the editorial boards of the Journal of Clinical Oncology and Oncologist; receives royalties from publishing UpToDate in Oncology (Up To Date, Inc. 2007–2009); has received non-industry-sponsored speaker honoraria; and receives research support from Millennium Pharmaceuticals, Inc., Schering-Plough Corp., and the NIH [KCA1254401 (PI), R01CA129371-01 (PI), 5K12CA90354-02 (Co-PI, PI), 1R13CA124293-01 (PI)].
PY - 2009/11
Y1 - 2009/11
UR - http://www.scopus.com/inward/record.url?scp=70449440499&partnerID=8YFLogxK
U2 - 10.1212/WNL.0b013e3181bf9907
DO - 10.1212/WNL.0b013e3181bf9907
M3 - Article
C2 - 19884580
AN - SCOPUS:70449440499
SN - 0028-3878
VL - 73
SP - 1509
EP - 1510
JO - Neurology
JF - Neurology
IS - 18
ER -